Vertex Pharmaceuticals Director Bruce I. Sachs Acquires Deferred Stock Units
VERTEX PHARMACEUTICALS INC / MA
Subscribe to track VRTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📊 Insider Transaction Report Issuer: VERTEX PHARMACEUTICALS INC / MA ($VRTX) Insider: Bruce I. Sachs (Director) Type: Acquisition (Award) Details: 92.694 Deferred Stock Units at $512.44 (~$47.50K) Significance: Low
Comprehensive Analysis
Transaction Summary
On October 15, 2026, Bruce I. Sachs, a member of the Board of Directors of Vertex Pharmaceuticals Inc ($VRTX), acquired 92.694 Deferred Stock Units (DSUs) at an implied price of $512.44 per unit, representing a total value of approximately $47,500.09. Following this grant transaction, Sachs directly holds 15,864.501 Deferred Stock Units.
Nature of the Award
As detailed in Footnote (F1), each deferred stock unit represents one share of common stock and settles in common stock upon the earliest occurrence of termination of board service, a change in control, or death/disability. This award is standard equity-based board compensation.
Market Significance
This transaction is categorized as Low significance. It represents a routine, scheduled board compensation grant (likely quarterly director retainers paid in equity) rather than an open-market discretionary purchase or sale.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.